The MND1 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B lymphocyte line, designed to disrupt the MND1 gene and abrogate its function. This product provides a heterogeneous loss-of-function model that retains the polyclonal nature of the edited pool, eliminating the need for single-cell cloning while enabling bulk-population phenotypic analyses. The polyclonal knockout cells are generated through CRISPR/Cas9-mediated gene disruption, resulting in a mixed population of cells harboring varied MND1 mutations. This format is particularly suited for early-stage functional studies, drug screening, and pathway interrogation where clonal variability may reflect a broader biological response rather than an artificial monoclonal artifact.
The parental Raji cell line is an Epstein-Barr virus (EBV)-positive Burkitt lymphoma-derived B lymphocyte model, extensively used in immunological and cancer research. Originating from a Burkitt lymphoma patient, Raji cells exhibit a mature B cell phenotype with surface immunoglobulin expression and constitutive activation of MYC, driven by a characteristic t(8;14) translocation. The EBV latency type III profile of Raji cells results in expression of the full set of latent viral genes, including LMP1 and EBNA2, which constitutively activate NF-??B and other survival pathways. This unique background makes Raji an informative system for studying B cell malignancies, viral oncogenesis, and the interplay between host genomic instability and tumor progression.
MND1 encodes a meiosis-specific protein that heterodimerizes with HOP2 (also known as PSMC3IP) to form a cofactor essential for homologous recombination. The MND1-HOP2 complex directly stimulates DMC1 and RAD51 recombinases, facilitating strand invasion and homology search during meiotic prophase I. Mechanistically, MND1 acts downstream of SPO11-induced double-strand breaks and is regulated by meiotic transcription factors such as STRA8 and DMRT1, as well as retinoic acid signaling. In addition to its canonical role in meiosis, MND1 interacts with BRCA2 and RPA, positioning it within a broader network that governs homologous recombination repair. Loss of MND1 impairs double-strand break resolution, leading to meiotic arrest and, in somatic contexts, contributes to genomic instability??a hallmark of many cancers, including those with MYC deregulation.
In the Raji lymphoma background, MND1 disruption creates a valuable model to investigate homologous recombination deficiency (HRD) in B cell malignancies. Given the centrality of MYC-driven replication stress and the EBV-mediated modulation of DNA damage responses, the MND1 knockout polyclonal cells allow dissection of how HR defects exacerbate genomic instability and affect tumor cell survival. This model may particularly illuminate synthetic lethal relationships, such as increased sensitivity to PARP inhibitors, and provide a platform to study how viral oncoproteins manipulate repair pathway choice. Furthermore, because Raji cells lack a normal meiotic program, this system enables the exploration of non-canonical MND1 functions outside of germline development.
Typical research applications include functional characterization of MND1 in non-meiotic cells, assessment of HR deficiency in B cell lymphoma, and synthetic lethality screens with DNA-damaging agents. Researchers can employ western blotting for MND1 and HOP2, RT-qPCR for residual MND1 transcript levels, and RAD51 foci immunofluorescence to monitor repair proficiency. Homologous recombination reporter assays (e.g., DR-GFP), comet assays, and cell viability curves following treatment with PARP inhibitors or genotoxic drugs provide functional readouts. Complementary RNA-seq and flow cytometry for B cell markers (e.g., CD19, CD20) enable comprehensive phenotyping of the knockout population. For further details, please contact Ascent Research.
